Close

Anti-CEA (SCA431) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX126)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 CEA (SCA431) h(28BBζ), which is constructed for the engineering of T cells to target human CEA. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-CEA antibody linked to a CD28 transmembrane domain/ endodomain and CD137 (4-1BB), CD3-zeta signaling domains. And the vector product was designed for the treatment of Pancreatic cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CEA
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Pancreatic cancer
  • Generation
  • Third
  • Vector Name
  • pSBCAR1
  • Vector Length
  • ~6kb
  • Vector Type
  • Sleeping Beauty (SB) transposon
  • Receptor Construction
  • scFv-CD28-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide costimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigennonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric 4-1BB and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • SCA431
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CEA
  • Synonyms
  • CEA; CD66e;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.3 CD4 T cells were modified with the CAR and used for adoptive transfer in this study.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.3 CD4 T cells were modified with the CAR and used for adoptive transfer in this study.

CAR expression was monitored by flow cytometry using a phycoerythrin-labeled anti-mouse IgG1 antibody and an allophycocyanin-conjugated antibody directed against CD4.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data ELISA

Fig.4 T cells with anti-CEA CAR (7.8 1021.0 105 cells/well) were coincubated at the indicated effector-to-tumor cell ratios with Panc02 cells with or without CEA expression for 48 hours.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.4 T cells with anti-CEA CAR (7.8 1021.0 105 cells/well) were coincubated at the indicated effector-to-tumor cell ratios with Panc02 cells with or without CEA expression for 48 hours.

Interferon-gamma in the culture supernatant as marker for T-cell activation was determined by enzyme-linked immunosorbent assay (ELISA).

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data FCM

Fig.5 Lung epithelia cells were isolated from the lung of CEAtg mice. Cells were stained for CEA and flow sorted before use in the study.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.5 Lung epithelia cells were isolated from the lung of CEAtg mice. Cells were stained for CEA and flow sorted before use in the study.

Mouse CEA Panc02 pancreatic carcinoma cells and fibrosarcoma CEA C15A3 cells were used for comparison.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data FuncS

Fig.6 CBLuc-marked Panc02 tumor cells and GLuc-marked T cells were recorded by bioluminescence imaging in the same mouse at the indicated days before and after T-cell transfer.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.6 CBLuc-marked Panc02 tumor cells and GLuc-marked T cells were recorded by bioluminescence imaging in the same mouse at the indicated days before and after T-cell transfer.

Data of bioluminescence signals were quantified.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data IHC

Fig.7 Tissues from CEAtg mice treated with CAR-engineered or nonmodified T cells were stained with H&E and recorded for CEA by antibody staining.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.7 Tissues from CEAtg mice treated with CAR-engineered or nonmodified T cells were stained with H&E and recorded for CEA by antibody staining.

Wild-type (wt) mice treated with CAR T cells were analyzed for comparison.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data FuncS

Fig.8 Lymphodepletion before therapy did not favor autoimmune colitis upon CAR T-cell infusion.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.8 Lymphodepletion before therapy did not favor autoimmune colitis upon CAR T-cell infusion.

Body weight of mice did not substantially alter during treatment.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data FCM

Fig.9 Transduction efficiency of CARS into Teffs and Tregs.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.9 Transduction efficiency of CARS into Teffs and Tregs.

Expression of the CEA-specific CAR was detected by incubating the cells with soluble CEA followed by staining with an anti-CEA antibody.

Blat, D., Zigmond, E., Alteber, Z., Waks, T., & Eshhar, Z. (2014). Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Molecular Therapy, 22(5), 1018-1028.

Complete CAR data FuncS

Fig.10 In vitro stimulation and cytotoxicity of CEA-specific CAR T cells.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.10 In vitro stimulation and cytotoxicity of CEA-specific CAR T cells.

Colorectal tumors were extracted from CEABAC-2 mice and dissociated to serve as target cells for CD4+ CAR Teff stimulation.

Blat, D., Zigmond, E., Alteber, Z., Waks, T., & Eshhar, Z. (2014). Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Molecular Therapy, 22(5), 1018-1028.

Complete CAR data Cyt

Fig.11 Cytotoxicity of CEA-specific CAR CD4+ Teffs, CD8+ Teffs, and Tregs towards CEA-expressing Capan-1 cells
transfected with firefly luciferase, as measured by bioluminescence signal intensity.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.11 Cytotoxicity of CEA-specific CAR CD4+ Teffs, CD8+ Teffs, and Tregs towards CEA-expressing Capan-1 cells transfected with firefly luciferase, as measured by bioluminescence signal intensity.

Control: Irrelevant CAR Teffs.

Blat, D., Zigmond, E., Alteber, Z., Waks, T., & Eshhar, Z. (2014). Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Molecular Therapy, 22(5), 1018-1028.

Complete CAR data FuncS

Fig.1 Severe weight loss and the eventual death of CEA-Tg mice transferred with CEA-specific CAR-T cells.

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.1 Severe weight loss and the eventual death of CEA-Tg mice transferred with CEA-specific CAR-T cells.

Cryostat sections of organs collected from mice at 17 day after tumor inoculation.

Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., ... & Shiku, H. (2016). Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology, 5(9), e1211218.

Complete CAR data FuncS

Fig.2 Increased efficacy of tumor growth suppression by CEA-specific CAR-T cells in preconditioned mice is associated with severe weight loss and eventual death of CEA-Tg mice, but not WT mice

CAR Construction : SCA431 scFv-28ζ Latest CAR Construction

Fig.2 Increased efficacy of tumor growth suppression by CEA-specific CAR-T cells in preconditioned mice is associated with severe weight loss and eventual death of CEA-Tg mice, but not WT mice

CAR-T cells prepared from CEA-Tg and WT mice and those mock-transduced T cells from WT mice were transferred into MC32a tumor-bearing CEA-Tg mice that also received fludarabine,cyclophosphamide, and total body irradiation. Body weight changes of CEA-Tg were analyzed at indicated time points.

Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., ... & Shiku, H. (2016). Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology, 5(9), e1211218.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CEA (SCA431) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX126). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.